Creating entirely new therapeutic vaccines for the treatment of cancer
DCPrime is dedicated to creating more effective immunotherapy products for the treatment of cancer. The company has developed a unique platform technology which allows the generation of off-the-shelf dendritic cell (DC)-based vaccines. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. With this powerful platform, DCPrime has the opportunity to become the gold standard for off-the-shelf dendritic cell product.
January 1, 2012
DCPrime BV expands management team
November 11, 2011
DCPrime BV: Kansen realiseren dankzij financiële steun
July 14, 2011
DCPrime BV has been granted € 1.4 million government loan for acute myeloid leukemia program
April 14, 2011
DCPrime BV initiates its first clinical study in acute myeloid leukemia patients
Latest News:
January 1, 2012
DCPrime BV expands management team
November 11, 2011
DCPrime BV: Kansen realiseren dankzij financiële steun
July 14, 2011
DCPrime BV has been granted € 1.4 million government loan for acute myeloid leukemia program
April 14, 2011
DCPrime BV initiates its first clinical study in acute myeloid leukemia patients
